Meta-analysis of Risk Factors for Venous Thromboembolism in Patients with Gynecologic Malignant Tumors
Jiewei Pan,Gang Zhao
2024-03-29
Abstract:Objective: This study aims to investigate the risk factors associated with the development of venous thromboembolism (VTE) in patients diagnosed with gynecologic malignant tumors. Methods: A comprehensive meta-analysis was conducted by searching databases such as The Cochrane Library, PubMed, EMbase, Web of Science, CNKI, etc., covering the period from January 2010 to January 2020. Inclusion and exclusion criteria were applied to identify relevant literature. Two researchers independently conducted literature screening, data extraction, and quality assessment of the included studies. Meta-analysis was performed using RevMan 5.3 software. The analyzed indicators included age, tumor diameter, diabetes, coronary heart disease, tumor staging, body mass index, hypertension, hospitalization time, and surgery time. In this meta-analysis, the inclusion criteria for the studies were as follows: (1) Study type: Case-control studies; (2) Study population: Patients with gynecologic malignant tumors who developed venous thromboembolism; (3) Study focus: Risk factors for venous thromboembolism in patients with gynecologic malignant tumors; (4) Publication type: Journal articles. The exclusion criteria were: (1) Non-journal articles; (2) Non-case-control studies.; (3) Literature published in different forms multiple times; (4) Literature with incomplete information such as abstracts, keywords, conclusions, and study results. To conduct a comprehensive literature search, multiple databases were searched, including The Cochrane Library, PubMed, EMbase, Web of Science, CNKI, etc. The reason for selecting the time frame from January 2010 to January 2020 was to focus on recent research and include the most up-to-date studies available within the specified period. This time frame ensures that the analysis considers the relevant literature published in the past decade, providing a comprehensive understanding of the risk factors for venous thromboembolism in patients with gynecologic malignant tumors. Results: The meta-analysis incorporated eight studies, comprising a total of 6,436 cases (793 in the study group and 5,643 in the control group). The results revealed that, compared to the control group, the study group exhibited statistically significant older age [OR=1.41, 95% CI (1.00, 1.98), P = .05], higher tumor staging [OR=1.37, 95% CI (1.04, 1.81), P = .03], elevated body mass index [OR=1.42, 95% CI (1.12, 1.81), P = .004], increased prevalence of hypertension [OR=1.72, 95% CI (1.30, 2.28), P = .0002], and prolonged surgery time [OR=1.37, 95% CI (1.02, 1.85), P = .04]. However, there were no statistically significant differences in tumor diameter [OR=0.52, 95% CI (0.05, 5.32), P = .58], diabetes prevalence [OR=1.32, 95% CI (0.42, 4.11), P = .64], coronary heart disease incidence [OR=1.16, 95% CI (0.91, 1.47), P = .23], and hospitalization time [OR=1.90, 95% CI (0.98, 3.69), P = .06] between the study group and the control group.Regarding the statistical terms used in the results, odds ratio (OR) is a measure of the association between an exposure (in this case, risk factors) and an outcome (venous thromboembolism). It compares the odds of the outcome occurring in the study group (patients with gynecologic malignant tumors who developed VTE) to the odds of the outcome occurring in the control group (patients with gynecologic malignant tumors who did not develop VTE). An OR greater than 1 indicates a higher odds of the outcome in the study group compared to the control group, while an OR less than 1 indicates a lower odds.Confidence intervals (CIs) provide a range of values within which the true population parameter (in this case, the true OR) is likely to fall. The 95% confidence interval is commonly used, and it represents the range within which we can be 95% confident that the true OR lies. If the CI includes the value 1, it suggests that there is no statistically significant difference between the study and control groups, while if the CI does not include 1, it indicates a statistically significant difference. Conclusion: Age, tumor staging, body mass index, hypertension, and surgery time emerge as significant risk factors for VTE in gynecologic malignant tumor surgery patients. Monitoring these risk factors can effectively facilitate risk assessment and prevention of VTE. These findings have important clinical implications. Firstly, they emphasize the importance of considering these risk factors during the assessment of VTE risk in patients with gynecologic malignancies. Healthcare professionals can use this information to identify high-risk patients and implement appropriate preventive measures. For example, older patients, those with advanced tumor staging, elevated body mass index, or hypertension may require closer monitoring and prophylactic strategies to reduce the risk of VTE. Furthermore, these findings can contribute to the development of targeted prevention strategies. By recognizing the specific risk factors associated with VTE in gynecologic malignancies, healthcare providers can implement interventions tailored to the individual patient's risk profile. This may include optimizing perioperative management, providing prophylactic anticoagulation, promoting early mobilization, and employing compression stockings or intermittent pneumatic compression devices.